According to a research article published in February 2024, certain GLP-1 RAs drugs like Semaglutide or Exenatide leverage subcutaneous delivery system to attain peak concentrations more quickly and ensure rapid absorption
For breast cancer survivors who face challenges like weight gain, insulin resistance, and metabolic issues after treatment, tirzepatide may offer important benefits
Always verify the expiration date before injection, and discard vials past their marked date
The intersection of obesity and IBD is increasingly recognised, with some evidence suggesting that excess weight may influence disease activity and treatment outcomes, though more research is needed in this area
Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis
Hyperphagia in BBS appears to result from multifactorial disruptions, whereby intrinsic defects in CCK signaling pathways and receptor function further exaggerated obesity-related resistance to satiety signals (31)